Will GlaxoSmithKline plc Be Back To Growth By 2016?

Growth at GlaxoSmithKline plc (LON: GSK) has been slipping, but it should be back soon.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A few years ago GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) was looking stronger than rival AstraZeneca, with its more promising pipeline and better acquisition strategy offering better protection from the loss of patent protection on key drugs.

But that’s been turned on its head since Pascal Soriot joined and revamped AstraZeneca, so what are the prospects like now for future growth at Glaxo?

After a couple of years of pretty much no change in earnings per share (EPS) from GlaxoSmithKline, there’s a hefty drop of 17% forecast for the year ending December 2014, and this close to year-end it’s unlikely to be far out.

Strong pound

At third-quarter time, core earnings per share came in 14% down at actual exchange rates, but at constant exchange rates the figure was only minus 2%. Like many multinationals reporting in Sterling, GlaxoSmithKline is suffering from the effects of a strong pound. But the firm expects “full year 2014 core EPS to be broadly similar to 2013” at constant exchange, suggesting that the business itself is really not that far off growth.

The Q3 dividend was held steady at 19p per share, but Glaxo expected to lift its full-year dividend as it has been doing year-on-year, and that lends more strength to its confidence in its longer-term growth potential.

Dividend forecasts suggest a yield of a very healthy 5.5% this year at today’s price levels of around 1,475p, and something very similar in 2015. But before we get too excited at that, it would be covered less than 1.2 times by forecast earnings for each of the two years.

Glaxo is clearly gearing its dividends to its expected future earnings growth, and there are strong signs we could be seeing that recovery coming very quickly, as the firm is in a period of intense restructuring that is expected to reduce costs by £1bn over three years — with half expecting to be realised by 2016.

The disposal of some non-core businesses looks set to continue too, which in the short term should raise some cash and in the longer term will hopefully beef up the company’s margins.

Growth worth buying?

What’s the price of that potential return to growth?

Well, Glaxo shares are on a year-end P/E of 16 dropping to 15.6 based on 2015 forecasts, and that’s only a little above the market average. On dividends alone that looks to be justified, but today’s yields won’t be sustainable unless that earnings growth really does get back on track.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »